Ekso Bionics

Ekso Bionics to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

Retrieved on: 
Thursday, February 17, 2022
GLOBE, Industry, Nasdaq, Paralysis, Twitter, Bionics, Company, Ekso Bionics, Mobile phone, San Francisco Bay Area

RICHMOND, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022.

Key Points: 
  • RICHMOND, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022.
  • ET to discuss the financial results and recent business developments.
  • Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics Announces Leadership Transition

Retrieved on: 
Friday, January 21, 2022
Alliance for Main Street Fairness, Forward-looking statement, Technology, IOT, Corporate development, Ekso Bionics, SGD, Business administration, Wireless repeater, SEC, COVID-19, COO, Organization, Nasdaq, Growth, Optimism, Bloomsburg University of Pennsylvania, CEO, GLOBE, Industry, Goal, Bionics, Paralysis, Telecommunication, Company, Sierra Wireless, Sale, LLC, Twitter, Director, Board, COVID, Management, San Francisco Bay Area, Telit

RICHMOND, Calif., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Jack Peurach, who has served as the Company’s Chief Executive Officer since 2018, has informed the Company’s Board of Directors (the “Board”) of his decision to leave the Company effective January 21, 2022 to pursue other endeavors. He has also stepped down from the Company’s Board effective January 21, 2022.

Key Points: 
  • On behalf of the entire Board, we thank him for his service to Ekso Bionics.
  • Steven has demonstrated deep commitment to the Company, having invested significant amounts of his personal capital since 2013, when he began working with Ekso Bionics.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.
  • To learn more about Ekso Bionics please visit the Companys website at www.eksobionics.com or refer to the Companys Twitter page at @EksoBionics.

Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, January 10, 2022
Traction, SEC, Growth, Industry, Patient, Paralysis, Ekso Bionics, Marketing, Awareness, Forward-looking statement, Bionics, Company, EVO, Nasdaq, Mission statement, COVID-19, Twitter, GLOBE, Mobile phone, Video game, Risk management, San Francisco Bay Area

RICHMOND, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2021.

Key Points: 
  • RICHMOND, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2021.
  • Our strong estimated fourth quarter 2021 revenue reflects continued momentum of our progress with leading inpatient rehabilitation operators across all regions and increased industrial orders, commented Jack Peurach, President and Chief Executive Officer of Ekso Bionics.
  • The anticipated results discussed in this press release are based on managements preliminary, unaudited analysis of financial results for the three months and year ended December 31, 2021.
  • The Company expects to report complete fourth quarter and full year 2021 financial results during the last week of February 2022.

Ekso Bionics to Participate at the H.C. Wainwright BioConnect Virtual Conference

Retrieved on: 
Tuesday, January 4, 2022
Company, GLOBE, Nasdaq, Ekso Bionics, Industry, Conference, Paralysis, Twitter, Bionics, San Francisco Bay Area

RICHMOND, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

Key Points: 
  • RICHMOND, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.
  • Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications.
  • Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

Ekso Bionics Appoints Corinna E. Lathan, Ph.D. to its Board of Directors

Retrieved on: 
Tuesday, December 28, 2021
Twitter, Growth, History of the University of Maryland, College Park, College Park, Associate, Bionics, Catholic University of America, Engineering, Ekso Bionics, Board, Catholic higher education, Robotics, GLOBE, Internet, Company, Augment, Biomedical engineering, Paralysis, SEC, PTC, Chairperson, Research, University, Board of directors, Nasdaq, Biomedicine, The, Forward-looking statement, Industry, Management, Risk management, San Francisco Bay Area

RICHMOND, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Corinna E. Lathan, Ph.D. to its Board of Directors, effective immediately.

Key Points: 
  • RICHMOND, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Corinna E. Lathan, Ph.D. to its Board of Directors, effective immediately.
  • I am delighted to join the Ekso Bionics Board and support the company in bringing pioneering solutions across medical and industrial applications, said Dr. Lathan.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.
  • To learn more about Ekso Bionics please visit the Companys website at www.eksobionics.com or refer to the Companys Twitter page at @EksoBionics.

Ekso Bionics Announces EksoNR Multi-Unit Order by Nebraska Fraternal Order of Eagles

Retrieved on: 
Thursday, December 16, 2021
Philosophy, Forward-looking statement, Hope, Technology, Solution, FDA, Neurosurgery, Fraternal order, CARF, Company, Brain, Gastroenterology, Elective surgery, Bionics, Stroke, Life, Physician, Population, Methodism, Spinal cord, Industry, Nasdaq, Paralysis, Service, Fraternal Order of Eagles, Kidney, Cancer, Commission on Accreditation of Rehabilitation Facilities, Adoption, Mount Zion, Spinal cord injury, SEC, Rehabilitation, Therapy, Patient, Accreditation, Ekso Bionics, Methodist Hospital, Organic, GLOBE, Commission, Twitter, Brain damage, Muscle, Diabetes, Bryan Health, Heart, Hospital, Pharmaceutical industry, Medical device, San Francisco Bay Area

RICHMOND, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Nebraska Chapter of the Fraternal Order of Eagles (“F.O.E.”), an international nonprofit community organization, has purchased two EksoNR devices on behalf of local Nebraska inpatient rehabilitation facilities.

Key Points: 
  • RICHMOND, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that the Nebraska Chapter of the Fraternal Order of Eagles (F.O.E.
  • Ekso Bionics is proud to partner with the Fraternal Order of Eagles in improving outcomes for patients through our innovative EksoNR technology, said Bill Shaw, Chief Commercial Officer of Ekso Bionics.
  • Supporting patients with spinal cord injury is one of the Fraternal Order of Eagles primary initiatives, and we take pride in this endeavor, said F.O.E.
  • We are grateful for the use of EksoNR through the generous donation of the Nebraska Chapter of the Fraternal Order of Eagles, said Samantha Penas, assistant therapy manager at Bryan Medical Center.

LUUM Provides Eyelash Extensions with Robots in Oakland, CA and Starts Crowdfunding

Retrieved on: 
Wednesday, November 24, 2021
Bionics, CEO, Technology, Time, Industry, AI, Robotics, University, Artificiality, Artificial intelligence, Moog, GLOBE, Adobe Inc., Ekso Bionics, Computer vision, University of California, Berkeley, Dash Robotics, Inc, CA, CMO, Cosmetics, Cryptocurrency

LUUM's Lash-Technology uses two robots to delicately apply lash extensions, using a technique similar to that of a human technician.

Key Points: 
  • LUUM's Lash-Technology uses two robots to delicately apply lash extensions, using a technique similar to that of a human technician.
  • The lash applicator uses a unique safety system which they claim makes it safer than human applied extensions.
  • Their goal is to give lash artists a tool that will allow them to provide their clients eyelash extensions in a fraction of the time currently possible.
  • Wink Robotics, Inc. doing business as LUUM develops robotic equipment for the beauty services industry, initially focusing on eyelash extensions, a widely popular beauty treatment.

Ekso Bionics Reports Third Quarter 2021 Results

Retrieved on: 
Tuesday, November 2, 2021
Ekso Bionics, Industry, Bionics, Mission statement, Twitter, Overalls, SEC, Conference, Income, Nasdaq, Forward-looking statement, Marketing, Company, COVID-19, Awareness, EVO, Research, Traction, GLOBE, Paralysis, Animal, Film, Lithium, Pharmaceutical industry, Ridesharing company, Reinsurance

RICHMOND, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended September 30, 2021.

Key Points: 
  • RICHMOND, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended September 30, 2021.
  • Revenue was $3.0 million for the quarter ended September 30, 2021, compared to $2.9 million for the same period in 2020.
  • Revenue in the third quarter of 2021 included approximately $2.7 million in EksoHealth revenue and approximately $0.3 million in EksoWorks revenue.
  • Gross profit for the quarter ended September 30, 2021 was $1.8 million, unchanged from the same period in 2020.

Ekso Bionics to Report Third Quarter 2021 Financial Results on November 2, 2021

Retrieved on: 
Tuesday, October 26, 2021
Ekso Bionics, Nasdaq, Twitter, Conference, GLOBE, Company, Industry, Paralysis, Bionics, Mobile phone

RICHMOND, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2021 after the close of trading on Tuesday, November 2, 2021.

Key Points: 
  • RICHMOND, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the Company), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2021 after the close of trading on Tuesday, November 2, 2021.
  • ET to discuss the financial results and recent business developments.
  • Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications.
  • Ekso Bionics is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO.

New Analysis from Global Industry Analysts Reveals Robust Growth for Construction Robots, with the Market to Reach $218.7 Million Worldwide by 2026

Retrieved on: 
Wednesday, October 13, 2021
Giant, Players, Forecasting, Husqvarna Group, Fastbrick Robotics, CAGR, Growth, Public infrastructure, Marketing, Intelligence, GIA, Autonomous Solutions, Limiting factor, Geography, Robotics, ASI, Cyberdyne Inc., SAN, Commercial, Demolition, Research, Ekso Bionics, Robotic arm, COVID-19, Pharmaceutical industry, Pet

SAN FRANCISCO, Oct. 13, 2021 /PRNewswire/-- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Construction Robots - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Oct. 13, 2021 /PRNewswire/-- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Construction Robots - Global Market Trajectory & Analytics" .
  • Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more.
  • The U.S. Market is Estimated at $30.7 Million in 2021, While China is Forecast to Reach $38.3 Million by 2026
    The Construction Robots market in the U.S. is estimated at US$30.7 Million in the year 2021.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.